Ionis Pharmaceuticals (IONS)

Company Description

Ionis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company’s broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. IONS’ partner, Genzyme, plans to commercialize its lead product, Kynamro, in the U.S. and Europe following regulatory approval. IONS’ patents provide strong and extensive protection for its drugs and technology.

2855 Gazelle Court
Carlsbad, CA 92010
United States



Get BioInvest's perspective on Ionis Pharmaceutical's CEO

Latest Company News

Stock Levels in Review: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Rives Journal - 12 hours ago Checking the Value Composite score for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), we see that the company has a rank of 84. [...]
Thu, Apr 27, 2017 5:37:00 PM, Continue reading at the source
Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio Motley Fool - 14 hours ago What makes the technology significant, and the company interesting to investors, is that it can potentially be applied to a wide variety of diseases, including some that have been considered "un-druggable" in the past. Focusing The Lens on Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS) Shares - Rockville Register Stanley T. Crooke Sells 22000 Shares of Ionis Pharmaceuticals Inc (IONS) Stock - The Cerbat Gem [...]
Thu, Apr 27, 2017 3:45:00 PM, Continue reading at the source
Ionis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast Yahoo Finance - Apr 26, 2017 CARLSBAD, Calif., April 26, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Tuesday, May 9 at 11:30 a.m. [...]
Wed, Apr 26, 2017 11:11:00 AM, Continue reading at the source
Stock Volatility Risk Alert: Ionis Pharmaceuticals Inc Stock Volatility Hits ... CML News - Apr 23, 2017 Before we cover the full analysis we make a quick alert here that Ionis Pharmaceuticals Inc (NASDAQ:IONS) has seen its stock price whip around at an escalated level. [...]
Sun, Apr 23, 2017 12:00:00 AM, Continue reading at the source
Investors Trading Alert: Ionis Pharmaceuticals, Inc.'s (IONS) Is stories - Apr 21, 2017 Ionis Pharmaceuticals, Inc.'s (IONS) witnessed a gain of 2.48% in recent trading period with closing price of $ 42.91. The company's last traded volume of 0.98 million shares was more it's an average volume of 1.68 million shares. Ionis Pharmaceuticals Inc (IONS) Position Decreased by Reliance Trust Co. of ... - The Cerbat Gem Insider Selling: Ionis Pharmaceuticals Inc (IONS) Chairman Sells 5500 Shares ... - Markets Daily [...]
Fri, Apr 21, 2017 11:04:00 AM, Continue reading at the source
Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics ... PR Newswire (press release) - Apr 18, 2017 CARLSBAD, Calif., April 18, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced a collaboration and license agreement with Suzhou Ribo Life Science Co. Ionis closes RNA therapeutics collaboration in China - Seeking Alpha Ionis, Ribo Partner to Develop RNA-Targeted Therapeutics in China - Genetic Engineering & Biotechnology News [...]
Tue, Apr 18, 2017 10:52:00 AM, Continue reading at the source
Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc. Motley Fool - Apr 13, 2017 Ionis recently announced plans to spin off its cardiovascular drugs, including volanesorsen and the Novartis-partnered drugs, into a separate company called Akcea. Ionis will get royalties ranging from the mid-teens to the mid-20s on the drug as well ... [...]
Thu, Apr 13, 2017 8:15:00 PM, Continue reading at the source
Is Ionis Pharmaceuticals Ready To Pop? Seeking Alpha - Apr 10, 2017 Ionis Pharmaceuticals (NASDAQ:IONS) is a biotech company which develops RNA-targeted therapeutics and has been operating for over 26 years. Ionis Pharmaceuticals Inc (IONS) Receives $42.93 Average Price Target from ... - The Cerbat Gem Friday Stock Price Swings: Ionis Pharmaceuticals, Inc.'s (IONS) - Is stories [...]
Mon, Apr 10, 2017 1:18:00 PM, Continue reading at the source
Why Ionis Pharmaceuticals Dropped 18.7% in March Motley Fool - Apr 4, 2017 After phase 3 data for its volanesorsen revealed some cases of low platelet counts, Goldman Sachs cut its rating on the company, and management announced a spin-off of some of its drugs, Ionis Pharmaceuticals (NASDAQ:IONS) shares declined 18.7% in ... Ionis Pharmaceuticals Inc (IONS) Cut to “Sell” at Vetr Inc. - The Cerbat Gem Technical analysis perspective: Alnylam Pharmaceuticals, Inc. (ALNY), Ionis ... - Post Analyst [...]
Tue, Apr 04, 2017 4:18:00 PM, Continue reading at the source
Ionis Pharmaceuticals to Present at Needham Healthcare Conference Yahoo Finance - Mar 29, 2017 CARLSBAD, Calif., March 29, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that management will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 in ... Ionis Pharmaceuticals Inc (IONS) Price Target Cut to $59.00 by Analysts at BMO ... - The Cerbat Gem Its time to give a fresh look to Ionis Pharmaceuticals, Inc. (IONS) and ... - USA Commerce Daily [...]
Wed, Mar 29, 2017 11:14:00 AM, Continue reading at the source